Atrial Fibrillation Data For Boehringer Ingelheim’s Dabigatran Due In Early 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm completes enrollment in RE-LY trial, one of seven in the Phase III RE-VOLUTION program for the investigational antithrombotic.